跳至主要内容
临床试验/NL-OMON27692
NL-OMON27692尚未招募不适用

The GRAVITY study: Are Glp-1 analogues in cRAniopharyngioma patients a Valid Intervention to Treat obesitY? A randomized controlled trial.

Erasmus MC0 个研究点目标入组 104 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Erasmus MC
入组人数
104

研究概览

简要总结

A

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients with craniopharyngioma, aged =16 years;
  • BMI =30 kg/m2;
  • No surgical intervention for craniopharyngioma one year before inclusion;
  • Adequate hormone replacement therapy (with or without growth hormone) in the past 4 weeks.

排除标准

  • Pregnancy (wish);
  • Breastfeeding or plan to breastfeed during treatment;
  • Allergy or oversensitivity for GLP-1 analogues or components;
  • Multiple Endocrine Neoplasia syndrome 2 (MEN2 syndrome);
  • Up to second degree family members with medullary thyroid carcinoma;
  • Gastroparesis or severe digestive problems;
  • History of or current pancreatitis;
  • Amylase or lipase above 2 times the upper normal range;
  • Active gallbladder disease;
  • Current depression or suicidal thoughts;
  • Liver failure;
  • Renal impairment measured by Glomerular Filtration Rate (GFR) value less than 30 ml/min/1,73 m6 (less than 60 ml/min/1,73 m^2 in subjects treated with Sodium-glucose Cotransporter 2 Inhibitors);
  • NYHA class IV heart failure;
  • Insulin-dependent diabetes mellitus;
  • Use of another GLP-1 analogue;
  • Succeeded bariatric surgery (=10% weight loss);
  • Extreme fear of needles.

研究者

发起方
Erasmus MC

相似试验